Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
about
Peripheral neuropathy: clinical and electrophysiological considerations.Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral NerveMyelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cellsCryptogenic sensory polyneuropathy.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Peripheral neuropathy in cancer patients.Paraproteinemic neuropathies.The role of sulfoglucuronosyl glycosphingolipids in the pathogenesis of monoclonal IgM paraproteinemia and peripheral neuropathy.Successful treatment of IgM paraproteinaemic neuropathy with fludarabineRituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.Autoimmunity to beta IV spectrin in paraneoplastic lower motor neuron syndromeRituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy.Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG.Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosisCellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.An update on monoclonal gammopathy and neuropathy.IgM monoclonal gammopathy-associated neuropathies with different IgM specificity.Incidence and spectrum of paraneoplastic neurological syndromes: single center study.Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS).Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study.Anti-myelin-associated glycoprotein peripheral neuropathy as the only presentation of low grade lymphoma: a case report.Cytomegalovirus is not associated with IgM anti-myelin-associated glycoprotein/sulphate-3-glucuronyl paragloboside antibody-associated neuropathy.Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy.Anti-heparan sulfate antibodies in neurological disease.Ganglioside agglutination immunoassay for rapid detection of autoantibodies in immune-mediated neuropathy.Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.Paraproteinemic neuropathy.Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy.
P2860
Q27693190-F6090C0E-F51E-4579-9990-B7E2D4EB4AA7Q30234567-AE6E6D5E-061B-4D99-8740-AEDB0F18C94CQ33252356-9DCABD84-94B2-4405-8641-C5F2CF2CB857Q33800466-EA366E5D-86B9-4FFB-BEBE-AA40F200BE58Q33878084-AEDCC66C-A7C9-4FE1-B612-3625B861B253Q34122035-88B453F6-6F2A-48AF-8B66-1BF46D68DA8EQ34280846-00260428-A7E4-448D-AC3B-282A83D1BD53Q34369520-DD366A16-4962-4FCF-82A1-5C70EEACDE3CQ35208842-0EFD6A65-26FB-4C7E-A128-509754AD2C50Q35451247-131DA6A6-A7C6-4FA0-99CE-BA9F3D839CFEQ35858046-5EE75138-7F18-4AC6-A493-BAEBBDB50F79Q36243856-EE2143B2-BF3E-446E-B98D-E90626BD5729Q36607310-D3291C92-55A4-49C3-9A84-475ADD9EF66DQ36658299-A5D81706-0AC7-47B7-8C41-B3B0BA15A97AQ36894111-27E816CD-CA0F-4F01-B249-7CD4B7585395Q37251063-EE3A8A59-4BF1-4FF5-8485-0D867B4DEEBEQ37381504-62272ECA-4D38-4ED3-914D-D3E42B72BABBQ37540582-FF21FDC4-6869-43D0-BE5D-BCEE9FCFF143Q37957050-F5A77783-CFDB-443F-8774-5C6F950A6A6FQ39790487-72D928D2-ACCD-4C77-B4B8-71BAF622A496Q40607170-1918EE87-EF60-4F85-8C33-0A2E66139498Q40747172-A01ACFE1-0656-48F5-85D9-AC6A78DC05CAQ41638338-80D41133-7EE0-4EE9-A7B0-916C70D76B63Q42268840-86F81528-BC06-4526-B270-BD23CC7E611FQ44486252-0BE074A3-9565-4F0E-A8AC-C9107C6D015FQ48269944-011815FD-7307-4579-BCB0-2190FCA6A21AQ48459227-A1E778D4-51F8-4037-A4B7-2FBAAC97E35AQ48925104-AEF12995-FCD6-4CA3-B5DB-E61A69CA5178Q50197158-48FE66B2-3CA0-4684-9AE5-1F0E33DE283AQ53791232-C4BD3F79-49B0-4C3E-8D1A-F8BE493E0DB6Q55117883-3673D969-98CB-4036-8529-5A1971DE047A
P2860
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
@en
type
label
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
@en
prefLabel
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
@en
P2860
P356
P1433
P1476
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
@en
P2093
P2860
P304
P356
10.1002/ANA.410370705
P478
37 Suppl 1
P577
1995-05-01T00:00:00Z